Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Common Stock Valuation Ratios (Price Multiples) 

Microsoft Excel

Current Valuation Ratios

IQVIA Holdings Inc., current price multiples

Microsoft Excel
IQVIA Holdings Inc. AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Moderna Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Pharmaceuticals, Biotechnology & Life Sciences Health Care
Selected Financial Data
Current share price (P) $180.01
No. shares of common stock outstanding 182,500,000
Growth rate (g) 8.50%
 
Earnings per share (EPS) $5.98
Next year expected EPS $6.49
Operating profit per share $9.86
Sales per share $78.96
Book value per share (BVPS) $31.59
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 30.11 60.96 23.04 14.63 35.50 136.48 19.50 10.49 675.31 66.70 20.66 32.72 20.70 22.07
Price to next year expected earnings 27.75 75.98 15.91 14.26 32.39 92.22 9.27 60.83 16.55 28.55 18.62 19.85
Price-earnings-growth (PEG) 3.54 0.51 5.65 3.70 2.84 0.80 6.91 0.83 2.24 1.85 1.98
Price to operating profit (P/OP) 18.26 23.24 19.59 16.12 32.36 110.75 14.52 17.38 104.67 636.64 20.18 28.60 16.53 17.22
Price to sales (P/S) 2.28 5.46 5.75 2.61 7.05 20.96 4.10 4.33 4.10 2.13 2.42 6.23 4.58 4.78 2.33
Price to book value (P/BV) 5.70 28.62 24.83 3.99 3.15 66.40 4.84 5.36 6.56 1.03 1.59 3.15 4.20 5.96 5.05

Based on: 10-K (reporting date: 2022-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

IQVIA Holdings Inc., historical price multiples

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Price to earnings (P/E) 38.65 45.78 132.09 166.58 107.95
Price to operating profit (P/OP) 23.44 31.75 50.41 40.95 37.73
Price to sales (P/S) 2.93 3.19 3.24 2.87 2.69
Price to book value (P/BV) 7.31 7.32 6.14 5.30 4.16

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. IQVIA Holdings Inc. P/E ratio decreased from 2020 to 2021 and from 2021 to 2022.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. IQVIA Holdings Inc. P/OP ratio decreased from 2020 to 2021 and from 2021 to 2022.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. IQVIA Holdings Inc. P/S ratio decreased from 2020 to 2021 and from 2021 to 2022.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. IQVIA Holdings Inc. P/BV ratio increased from 2020 to 2021 but then slightly decreased from 2021 to 2022.

Price to Earnings (P/E)

IQVIA Holdings Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 185,722,621 190,485,264 191,281,286 192,339,093 197,599,861
Selected Financial Data (US$)
Net income attributable to IQVIA Holdings Inc. (in millions) 1,091 966 279 191 259
Earnings per share (EPS)2 5.87 5.07 1.46 0.99 1.31
Share price1, 3 227.03 232.18 192.66 165.42 141.49
Valuation Ratio
P/E ratio4 38.65 45.78 132.09 166.58 107.95
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 22.62 22.07 40.17 17.82
Amgen Inc. 19.56 21.05 18.82 17.07
Bristol-Myers Squibb Co. 23.97 20.92 41.99
Danaher Corp. 25.65 29.94 44.49 38.34
Eli Lilly & Co. 50.08 40.66 31.95 16.19
Gilead Sciences Inc. 22.68 12.36 641.48 16.45
Johnson & Johnson 22.97 20.93 28.92 25.99
Merck & Co. Inc. 19.21 14.78 26.72 20.60
Moderna Inc. 6.43 5.00
Pfizer Inc. 7.58 11.76 19.62 11.63
Regeneron Pharmaceuticals Inc. 19.68 8.37 15.09 19.86
Thermo Fisher Scientific Inc. 30.55 27.35 27.89 33.36
P/E Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 19.24 17.76 37.29 20.82
P/E Ratio, Industry
Health Care 20.36 19.87 29.50 21.10

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
EPS = Net income attributable to IQVIA Holdings Inc. ÷ No. shares of common stock outstanding
= 1,091,000,000 ÷ 185,722,621 = 5.87

3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.

4 2022 Calculation
P/E ratio = Share price ÷ EPS
= 227.03 ÷ 5.87 = 38.65

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. IQVIA Holdings Inc. P/E ratio decreased from 2020 to 2021 and from 2021 to 2022.

Price to Operating Profit (P/OP)

IQVIA Holdings Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 185,722,621 190,485,264 191,281,286 192,339,093 197,599,861
Selected Financial Data (US$)
Income from operations (in millions) 1,799 1,393 731 777 741
Operating profit per share2 9.69 7.31 3.82 4.04 3.75
Share price1, 3 227.03 232.18 192.66 165.42 141.49
Valuation Ratio
P/OP ratio4 23.44 31.75 50.41 40.95 37.73
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 14.78 14.21 16.32 10.82
Amgen Inc. 13.40 16.24 14.96 13.84
Bristol-Myers Squibb Co. 18.29 19.84 24.42
Danaher Corp. 20.97 25.14 36.91 34.47
Eli Lilly & Co. 43.88 35.70 32.66 27.08
Gilead Sciences Inc. 14.21 7.76 19.38 20.66
Johnson & Johnson 17.62 18.68 21.84 19.83
Merck & Co. Inc. 15.55 15.39 23.89 17.47
Moderna Inc. 5.71 4.59
Pfizer Inc. 6.80 13.30 23.12 14.36
Regeneron Pharmaceuticals Inc. 18.01 7.55 14.82 19.01
Thermo Fisher Scientific Inc. 25.30 21.07 22.81 26.84
P/OP Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 15.37 15.55 27.63 18.65
P/OP Ratio, Industry
Health Care 15.88 16.54 21.85 17.29

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= 1,799,000,000 ÷ 185,722,621 = 9.69

3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.

4 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 227.03 ÷ 9.69 = 23.44

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. IQVIA Holdings Inc. P/OP ratio decreased from 2020 to 2021 and from 2021 to 2022.

Price to Sales (P/S)

IQVIA Holdings Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 185,722,621 190,485,264 191,281,286 192,339,093 197,599,861
Selected Financial Data (US$)
Revenues (in millions) 14,410 13,874 11,359 11,088 10,412
Sales per share2 77.59 72.84 59.38 57.65 52.69
Share price1, 3 227.03 232.18 192.66 165.42 141.49
Valuation Ratio
P/S ratio4 2.93 3.19 3.24 2.87 2.69
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 4.61 4.53 4.05 4.22
Amgen Inc. 5.17 5.10 5.64 6.03
Bristol-Myers Squibb Co. 3.29 3.16 3.16 5.52
Danaher Corp. 5.79 6.37 7.01 6.29
Eli Lilly & Co. 10.96 8.01 8.06 6.03
Gilead Sciences Inc. 3.86 2.85 3.24 4.00
Johnson & Johnson 4.34 4.66 5.15 4.79
Merck & Co. Inc. 4.71 3.96 3.93 4.33
Moderna Inc. 2.92 3.45 309.64
Pfizer Inc. 2.37 3.18 4.50 3.66
Regeneron Pharmaceuticals Inc. 7.01 4.20 6.24 5.34
Thermo Fisher Scientific Inc. 4.73 5.39 5.52 4.83
P/S Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.44 4.42 5.00 4.79
P/S Ratio, Industry
Health Care 2.15 2.28 2.25 2.13

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= 14,410,000,000 ÷ 185,722,621 = 77.59

3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.

4 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 227.03 ÷ 77.59 = 2.93

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. IQVIA Holdings Inc. P/S ratio decreased from 2020 to 2021 and from 2021 to 2022.

Price to Book Value (P/BV)

IQVIA Holdings Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 185,722,621 190,485,264 191,281,286 192,339,093 197,599,861
Selected Financial Data (US$)
Equity attributable to IQVIA Holdings Inc.’s stockholders (in millions) 5,765 6,042 6,001 6,003 6,714
Book value per share (BVPS)2 31.04 31.72 31.37 31.21 33.98
Share price1, 3 227.03 232.18 192.66 165.42 141.49
Valuation Ratio
P/BV ratio4 7.31 7.32 6.14 5.30 4.16
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 15.52 16.53 14.18
Amgen Inc. 35.01 18.51 14.53 13.84
Bristol-Myers Squibb Co. 4.88 4.07 3.55 2.80
Danaher Corp. 3.64 4.16 3.93 3.72
Eli Lilly & Co. 29.36 25.28 35.07 51.67
Gilead Sciences Inc. 4.90 3.65 4.33 3.93
Johnson & Johnson 5.37 5.90 6.72 6.61
Merck & Co. Inc. 6.07 5.05 7.46 7.83
Moderna Inc. 2.81 4.31 24.16 8.21
Pfizer Inc. 2.48 3.35 2.98 3.00
Regeneron Pharmaceuticals Inc. 3.77 3.60 4.81 3.79
Thermo Fisher Scientific Inc. 4.83 5.18 5.15 4.16
P/BV Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.54 5.66 6.13 5.74
P/BV Ratio, Industry
Health Care 4.66 4.78 4.66 4.41

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
BVPS = Equity attributable to IQVIA Holdings Inc.’s stockholders ÷ No. shares of common stock outstanding
= 5,765,000,000 ÷ 185,722,621 = 31.04

3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.

4 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 227.03 ÷ 31.04 = 7.31

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. IQVIA Holdings Inc. P/BV ratio increased from 2020 to 2021 but then slightly decreased from 2021 to 2022.